2015 Deal Sheet
A select list of transactions announced in 2015 including acquisitions, commercial and development collaborations, out-licensing agreements, equity investments, combination study agreements, spin-outs and academic collaborations

FIRST QUARTER
Kite Pharma
Preclinical cancer immunotherapy collaboration to advance the application of novel Chimeric Antigen Receptor (CAR) T-cell therapies

MD Anderson Cancer Center
Preclinical agreement to develop BiTE® therapies for myelodysplastic syndrome

NantCell
Out-license of AMG 479, an anti-IGF-1R antibody previously in Phase 3 development for pancreatic cancer

Celimmune
Out-license and option agreement of AMG 714, an anti-IL-15 antibody in development for certain forms of celiac disease

venBio
Limited partner equity investment managed through Amgen Ventures in venBio limited partnership fund

SECOND QUARTER
Merck
Phase 1b/3 combination study in head and neck cancer with pembrolizumab and talimogene laherparepvec

Precision BioSciences
Amgen Ventures investment in Series A financing of genome editing company

Roche/Genentech
Phase 1b combination study in colorectal cancer and triple negative breast cancer with talimogene laherparepvec and atezolizumab

Acerta Pharma
Equity investment in a biotechnology company pursuing a novel BTK inhibitor for the treatment of certain hematological malignancies and inflammatory disorders

AmBER Program
Amgen program to advance basic biology research with more than 1,000 tools and resources available to academic institutions

Redmile Group
Limited partner investment supported by Amgen Ventures in digital health limited partnership fund

Kezar Life Sciences
Immunoproteasome inhibitor program spun out from Amgen subsidiary Onyx Pharmaceuticals to focus on autoimmune disease

Open Monoclonal Technology
In-license of proprietary human antibody generation platforms known as OmniAb™

Amgen Business Development
Amgen is committed to partnering with innovators in the fight against serious illness. Amgen’s business development team brings together deep scientific, financial, deal, partnership, and integration expertise—along with an ability to bring the right people inside Amgen to the right conversations.

Business Development plays a critical role in the execution of Amgen’s growth strategy. From the early-stage innovations we fund through Amgen Ventures to the integration and alliance management work we engage in once an agreement is reached, Amgen Business Development is organized to effectively manage the process of working with partners every step of the way.

Focused Areas of Interest
- Bone Health
- Cardiovascular
- Inflammation
- Nephrology
- Neuroscience
- Oncology
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgenbd.com